OSTEOPOROSIS TREATMENT ADHERENCE: RESULTS FROM A RETROSPECTIVE COHORT STUDY

Treatment adherence in patients with osteoporosis (OP) is rather low throughout the world, and 50 to 75% of patients stop taking anti-osteoporotic drugs within a year after therapy prescription.Objective: to establish determinants that affect patient adherence to OP therapy.Subjects and methods. The...

Full description

Saved in:
Bibliographic Details
Main Authors: O. A. Nikitinskaya, N. V. Toroptsova, E. L. Nasonov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2019-09-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/2753
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850043069372563456
author O. A. Nikitinskaya
N. V. Toroptsova
E. L. Nasonov
author_facet O. A. Nikitinskaya
N. V. Toroptsova
E. L. Nasonov
author_sort O. A. Nikitinskaya
collection DOAJ
description Treatment adherence in patients with osteoporosis (OP) is rather low throughout the world, and 50 to 75% of patients stop taking anti-osteoporotic drugs within a year after therapy prescription.Objective: to establish determinants that affect patient adherence to OP therapy.Subjects and methods. The investigation enrolled 150 women older than 50 years (mean age, 68.8±9.4 years) with OP duration of ≥3 years who had made an outpatient visit to the V.A. Nasonova Research Institute of Rheumatology. Their examination consisted of a survey using a specially designed questionnaire. Treatment adherence was evaluated, by using the data on the duration of treatment for OP within 3 years prior to the study inclusion, as well as by calculating the drug use index.Results and discussion. During 3 years, 94 (63%) female patients were adherent to OP treatment, including those who took zoledronic acid (78%), denosumab (75%), and alendronate or ibandronate (60%); therapy with antiosteoporotic drugs was changed in 53% of patients. The most common reason for missing or discontinuing treatment was poor drug tolerance (33%); and that for self-replacement of recommended drugs was their cost (75%). Age, education, marital status, income, duration of disease and length of treatment, a familial history of fractures or a hip fracture, the number of concomitant diseases, and the total number of drugs taken did not affect medication adherence. Patients who were more adherent to OP treatment were those who underwent determination of serum vitamin D levels (p=0.009), calculation of a 10-year absolute osteoporotic fracture risk according to the FRAX® algorithm (p=0.022), an annual bone densitometry examination (p=0.0158) and, more often than annually, biochemical blood tests (p=0.0043), as well as those who had visited their physician 3 times or more during the estimated period (p=0.003). There were more people adherent to OP treatment among the patients receiving the parenteral formulations of drugs than among those who took drugs as tablets (p=0.036). Educational materials, brochures, and lectures on OP and a follow-up in a specialized center did not ensure that treatment adherence could be significantly increased (p>0.05).Conclusion. Patient adherence to OP therapy is positively influenced by determination of serum vitamin D levels, calculation of a 10-year absolute osteoporotic fracture risk (FRAX®), annual therapeutic monitoring using bone densitometry and results of biochemical blood tests, regular visits to a physician  who follows up the patient for OP, as well as simplification of a dosing regimen and administration of the parenteral formulations of drugs used to treat OP.
format Article
id doaj-art-249abdfde3d94051bedd491dcd0b16e3
institution DOAJ
issn 1995-4484
1995-4492
language Russian
publishDate 2019-09-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj-art-249abdfde3d94051bedd491dcd0b16e32025-08-20T02:55:20ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922019-09-0157441542010.14412/1995-4484-2019-415-4202512OSTEOPOROSIS TREATMENT ADHERENCE: RESULTS FROM A RETROSPECTIVE COHORT STUDYO. A. Nikitinskaya0N. V. Toroptsova1E. L. Nasonov2V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology, I.M. Sechenov First Moscow State Medical University (Sechenov University)Treatment adherence in patients with osteoporosis (OP) is rather low throughout the world, and 50 to 75% of patients stop taking anti-osteoporotic drugs within a year after therapy prescription.Objective: to establish determinants that affect patient adherence to OP therapy.Subjects and methods. The investigation enrolled 150 women older than 50 years (mean age, 68.8±9.4 years) with OP duration of ≥3 years who had made an outpatient visit to the V.A. Nasonova Research Institute of Rheumatology. Their examination consisted of a survey using a specially designed questionnaire. Treatment adherence was evaluated, by using the data on the duration of treatment for OP within 3 years prior to the study inclusion, as well as by calculating the drug use index.Results and discussion. During 3 years, 94 (63%) female patients were adherent to OP treatment, including those who took zoledronic acid (78%), denosumab (75%), and alendronate or ibandronate (60%); therapy with antiosteoporotic drugs was changed in 53% of patients. The most common reason for missing or discontinuing treatment was poor drug tolerance (33%); and that for self-replacement of recommended drugs was their cost (75%). Age, education, marital status, income, duration of disease and length of treatment, a familial history of fractures or a hip fracture, the number of concomitant diseases, and the total number of drugs taken did not affect medication adherence. Patients who were more adherent to OP treatment were those who underwent determination of serum vitamin D levels (p=0.009), calculation of a 10-year absolute osteoporotic fracture risk according to the FRAX® algorithm (p=0.022), an annual bone densitometry examination (p=0.0158) and, more often than annually, biochemical blood tests (p=0.0043), as well as those who had visited their physician 3 times or more during the estimated period (p=0.003). There were more people adherent to OP treatment among the patients receiving the parenteral formulations of drugs than among those who took drugs as tablets (p=0.036). Educational materials, brochures, and lectures on OP and a follow-up in a specialized center did not ensure that treatment adherence could be significantly increased (p>0.05).Conclusion. Patient adherence to OP therapy is positively influenced by determination of serum vitamin D levels, calculation of a 10-year absolute osteoporotic fracture risk (FRAX®), annual therapeutic monitoring using bone densitometry and results of biochemical blood tests, regular visits to a physician  who follows up the patient for OP, as well as simplification of a dosing regimen and administration of the parenteral formulations of drugs used to treat OP.https://rsp.mediar-press.net/rsp/article/view/2753osteoporosistreatment of osteoporosistreatment adherencefactors influencing treatment adherence
spellingShingle O. A. Nikitinskaya
N. V. Toroptsova
E. L. Nasonov
OSTEOPOROSIS TREATMENT ADHERENCE: RESULTS FROM A RETROSPECTIVE COHORT STUDY
Научно-практическая ревматология
osteoporosis
treatment of osteoporosis
treatment adherence
factors influencing treatment adherence
title OSTEOPOROSIS TREATMENT ADHERENCE: RESULTS FROM A RETROSPECTIVE COHORT STUDY
title_full OSTEOPOROSIS TREATMENT ADHERENCE: RESULTS FROM A RETROSPECTIVE COHORT STUDY
title_fullStr OSTEOPOROSIS TREATMENT ADHERENCE: RESULTS FROM A RETROSPECTIVE COHORT STUDY
title_full_unstemmed OSTEOPOROSIS TREATMENT ADHERENCE: RESULTS FROM A RETROSPECTIVE COHORT STUDY
title_short OSTEOPOROSIS TREATMENT ADHERENCE: RESULTS FROM A RETROSPECTIVE COHORT STUDY
title_sort osteoporosis treatment adherence results from a retrospective cohort study
topic osteoporosis
treatment of osteoporosis
treatment adherence
factors influencing treatment adherence
url https://rsp.mediar-press.net/rsp/article/view/2753
work_keys_str_mv AT oanikitinskaya osteoporosistreatmentadherenceresultsfromaretrospectivecohortstudy
AT nvtoroptsova osteoporosistreatmentadherenceresultsfromaretrospectivecohortstudy
AT elnasonov osteoporosistreatmentadherenceresultsfromaretrospectivecohortstudy